Acute Myeloid Leukemia and Measurable Residual Disease
The sponsor’s clinical research is centered on acute myeloid leukemia cases with persistent or recurrent measurable residual disease after frontline treatment, with attention to patients whose disease remains detectable despite prior intensive therapy.
- MRD persistence
- MRD reappearance
- Frontline chemotherapy
Its research focus includes disease monitoring in AML during post-treatment follow-up, particularly where residual disease status may influence subsequent therapeutic decisions.
Allogeneic Hematopoietic Cell Transplantation
Another key area of interest is allogeneic hematopoietic cell transplantation, especially in patients entering transplant with detectable MRD and in those evaluated for treatment before transplantation.
- Pre-transplant MRD
- First complete remission
- Transplant-related risk stratification
The sponsor’s work addresses transplant-adjacent disease control in AML subtypes where residual leukemia burden remains clinically relevant.
European LeukemiaNet-Defined Risk Subtypes
The research landscape also covers European LeukemiaNet risk categories, including favorable and non-favorable AML subtypes, with patient selection shaped by prognostic classification and residual disease status.
- Favorable ELN subtype
- Non-favorable ELN subtype
- Prognostic classification
This area reflects an interest in aligning therapeutic decisions with biologic risk features and disease persistence in acute myeloid leukemia.
Hematologic Oncology and Targeted Combination Therapy
The sponsor is involved in hematologic oncology research with a focus on treatment approaches combining venetoclax and azacitidine for residual disease control in AML.
- Venetoclax
- Azacitidine
- Residual disease clearance
Its clinical interest lies in therapies directed at MRD clearance in patients whose leukemia remains detectable after standard treatment or before transplant.
